Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.40 |
| ▸ | FURIN | P09958 | 4/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | NPY4R | P50391 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24224636 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL22138625 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL23943282 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL27197502 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL25450085 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL24476142 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL22128021 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL22128022 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL32667737 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL21570028 | 0.94 | FAP (0.39) | FAPFURINMAP1LC3BHTTNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365263-B2 | Bifunctional cytotoxic agents containing the CTI pharmacophore | PFIZER INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-10391182-B2 | Bifunctional cytotoxic agents | PFIZER INC. (US) | 2019-08-27 | — | — | US | disclosed |
| WO-2016151432-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE | PFIZER INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| US-20160271270-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE | PFIZER INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PAICS, CYTH3, CYTH2 | FAP 2415/4885FURIN 3455/4885MAP1LC3B 1741/4885 |
| US-20160271270-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE | CCNI, TTI1, TTI2 | FAP 4221/4885FURIN 2289/4885MAP1LC3B 194/4885 |
| US-10391182-B2 | Bifunctional cytotoxic agents | PAICS, CYTH3, CYTH2 | FAP 2415/4885FURIN 3455/4885MAP1LC3B 1741/4885 |
| US-11365263-B2 | Bifunctional cytotoxic agents containing the CTI pharmacophore | CCNI, TTI1, TTI2 | FAP 4221/4885FURIN 2289/4885MAP1LC3B 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.